文献速递前列腺癌

基于多参数前列腺磁共振与术前特征预测前列腺癌病理肿瘤大小

Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings.
PubMed 文献 · J Urol · 2020-10-07

本研究纳入441例前列腺癌患者的461个病灶,比较多参数磁共振(mpMRI)测量的肿瘤大小与根治术后全mount病理肿瘤大小。结果显示mpMRI consistently低估病理肿瘤大小(平均1.57 cm vs 2.37 cm,p<0.001),且低估程度在放射学肿瘤较小和PI-RADSv2评分较低时更明显。活检GG5、PI-RADSv2 5及较高PSA密度与更大的病理肿瘤独立相关。

要点

  • 肿瘤越小、PI-RADSv2评分越低,低估程度越明显。
  • 活检GG5、PI-RADSv2 5及高PSA密度提示病理肿瘤更大。

核心结论

  • 多参数MRI频繁低估前列腺癌病理肿瘤大小,低估程度随放射学肿瘤变小和PI-RADSv2评分降低而增加。
  • 局灶治疗中,对小肿瘤和低PI-RADSv2病灶可能需要更大的消融边缘。

研究设计与样本

  • 单臂研究队列,纳入连续活检证实前列腺癌且mpMRI显示PI-RADSv2≥3索引肿瘤并接受根治性前列腺切除术的患者。
  • 共分析441名男性的461个连续病灶。

主要发现

  • 平均放射学肿瘤大小1.57 cm,平均病理肿瘤大小2.37 cm(p<0.001)。
  • 放射学肿瘤大小始终低估病理肿瘤大小,且与术前协变量无关。
  • 活检GG5相比GG1病理肿瘤平均大0.37 cm(p=0.014)。
  • PI-RADSv2 5病灶相比PI-RADSv2 4病理肿瘤平均大0.26 cm(p=0.006)。
  • 较高PSA密度与更大病理肿瘤相关;放射学与病理肿瘤大小的相关系数范围为0.1至0.65。

临床怎么用

  • 在局灶治疗规划时,应考虑到mpMRI低估肿瘤大小的可能性。
  • 对于放射学肿瘤较小或PI-RADSv2评分较低的病灶,可能需要扩大消融边缘。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oncologic efficacy of focal therapies in prostate cancer depends heavily on accurate tumor size estimation. We aim to evaluate the agreement between radiologic tumor size and pathological tumor size, and identify predictors of pathological tumor size. MATERIALS AND METHODS: This single arm study cohort included all consecutive patients with biopsy proven prostate cancer and a corresponding PI-RADS®v2 3 or greater index tumor on multiparametric magnetic resonance imaging who subsequently underwent radical prostatectomy. Radiologic tumor size was defined as maximum tumor diameter on multiparametric magnetic resonance imaging and compared to whole mount histopathology tumor correlates. The difference between radiologic tumor size and pathological tumor size was assessed, and clinical, pathological and radiographic predictors of pathological tumor size were examined. RESULTS: A total of 461 consecutive lesions in 441 men were included for statistical analysis. Mean radiologic tumor size and pathological tumor size was 1.57 and 2.37 cm, respectively (p <0.001). Radiologic tumor size consistently underestimated pathological tumor size regardless of the preoperative covariates, and the degree of underestimation increased with smaller radiologic tumor size and lower PI-RADSv2 scores. Pathological tumor size was significantly larger for biopsy Gleason Grade Group (GG) 5 compared to GG1 (mean change 0.37 cm, p=0.014), PI-RADSv2 5 lesions compared to PI-RADSv2 4 (mean change 0.26, p=0.006) and higher prostate specific antigen density. The correlations between radiologic tumor size vs pathological tumor size according to biopsy GG and radiologic covariates were generally low with correlation coefficients ranging between 0.1 and 0.65. CONCLUSIONS: Multiparametric magnetic resonance imaging frequently underestimates pathological tumor size and the degree of underestimation increases with smaller radiologic tumor size and lower PI-RADSv2 scores. Therefore, a larger ablation margin may be required for smaller tumors and lesions with lower PI-RADSv2 scores. These variables must be considered when estimating treatment margins in focal therapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Pooli A, Johnson DC, Shirk J, et al. Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. J Urol. 2020. PMID: 33026934. doi:10.1097/JU.0000000000001389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。